TokenPost·
Pfizer Faces 16% EPS Decline Estimate as Q3 Report Nears
Analysts project revenue of $15.88 billion, down 4.6%, as investors look for updates on cost cuts, drug exclusivity and a Metsera-linked obesity candidate.
More news
- TokenPostCircle and Paxos Freeze Nearly $7 Million Tied to Mercado Bitcoin Incident
- TokenPostJay Woods Identifies Fortinet's $127.40 Low as Key Support
- TokenPostiShares Government Money Market ETF Sets Oct. 29 Payment Date
- TokenPostIDEXX Raises 2026 Outlook After Third-Quarter Revenue Reaches $1.214 Billion
- TokenPostGeoPark Activates Venezuela Contract as Gilinski Moves Toward Control
- Crypto BriefingOpenRouter crosses a 10 quadrillion annual token run rate